Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration - PubMed (original) (raw)

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration

D G Brockstedt et al. Clin Immunol. 1999 Jul.

Free article

Abstract

Recombinant adeno-associated virus (rAAV) is a replication-defective parvovirus which is being explored as a vector for gene therapy because of its broad host range, excellent safety profile, and durable transgene expression in infected hosts. rAAV has also been reported by several groups to induce little or no immune response to its encoded transgene products. In this study we examined the immunogenicity of rAAV by studying the immune response of C57BL/6 mice to a single dose of rAAV-encoding ovalbumin (AAV-Ova) administered by a variety of routes. Mice injected with AAV-Ova intraperitoneally (ip), intravenously, or subcutaneously developed potent ovalbumin-specific cytotoxic T lymphocytes (CTL) as well as anti-ovalbumin antibodies and antibodies to AAV. In contrast, mice injected with AAV-Ova intramuscularly developed a humoral response to the virus and the transgene but minimal ovalbumin-specific CTLs. The induced CTL response after ip administration of AAV-Ova protected mice against a subsequent tumor challenge with an ovalbumin-transfected B16 melanoma cell line. Studies of the mechanism by which AAV-Ova induces CTL confirmed that the virus delivers the transgene product into the classical MHC class I pathway of antigen processing. Mice that previously had been exposed to rAAV vectors failed to develop ovalbumin-specific CTL following administration of AAV-Ova. Analysis of these mice revealed the presence of circulating anti-AAV antibodies that blocked rAAV transduction in vitro and inhibited CTL induction in vivo. These results suggest a possible role for rAAV in the immunotherapy of malignancies and viral infections, although induced antibody responses to AAV may limit its ability to be administered for repeated vaccinations.

PubMed Disclaimer

Cited by

CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells.
Zhang Y, Chirmule N, Gao Gp, Wilson J. Zhang Y, et al. J Virol. 2000 Sep;74(17):8003-10. doi: 10.1128/jvi.74.17.8003-8010.2000. J Virol. 2000. PMID: 10933709 Free PMC article.
Inhibition of melanoma growth by subcutaneous administration of hTERTC27 viral cocktail in C57BL/6 mice.
Huo L, Yao H, Wang X, Wong GW, Kung HF, Lin MC. Huo L, et al. PLoS One. 2010 Sep 13;5(9):e12705. doi: 10.1371/journal.pone.0012705. PLoS One. 2010. PMID: 20856939 Free PMC article.
Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver.
Qiao C, Yuan Z, Li J, He B, Zheng H, Mayer C, Li J, Xiao X. Qiao C, et al. Gene Ther. 2011 Apr;18(4):403-10. doi: 10.1038/gt.2010.157. Epub 2010 Dec 9. Gene Ther. 2011. PMID: 21150938 Free PMC article.
A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation.
Palmer GA, Brogdon JL, Constant SL, Tattersall P. Palmer GA, et al. J Virol. 2004 Feb;78(3):1101-8. doi: 10.1128/jvi.78.3.1101-1108.2004. J Virol. 2004. PMID: 14722265 Free PMC article.
Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.
Adriouch S, Franck E, Drouot L, Bonneau C, Jolinon N, Salvetti A, Boyer O. Adriouch S, et al. Front Microbiol. 2011 Sep 29;2:199. doi: 10.3389/fmicb.2011.00199. eCollection 2011. Front Microbiol. 2011. PMID: 22046170 Free PMC article.

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration - PubMed (original) (raw)